About the Author: Jonathan Govette

CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What Iโ€™ve Learned Along the Way I help patients get the care they need earlier, preventing late-stage cancer. That's been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn't fall through the cracks. At Oatmeal Health, it's lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead. Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs. Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology. I'm a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren't scientific. They're operational. We're hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out. When I'm not working, I'm traveling, mentoring, and keeping up with one very energetic husky. ๐Ÿพ Substack - The Oatmeal Bite: Millions of patients get less care because of who they are, where they live, or how they look. I'm fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates. Jonathan Govette CEO of Oatmeal Health Substack: https://oatmealhealthjonathangovette.substack.com/

Shield Blood Test: 90M Americans Covered

By |September 13th, 2026|

90 million Americans can now screen for colorectal cancer with a blood draw. ๐Ÿฉธ This is the access story nobody is talking about enough. According to a September 1 announcement via Business Wire, Carelon Healthcare Services will cover Guardant Health's Shield blood test for colorectal cancer screening, effective November 15. Carelon is one of the largest specialty benefits managers in the country, providing medical benefit management to Blue Cross Blue Shield plans across 26 states. That single policy decision pushes total covered lives for Shield to approximately 90 million people, representing 75% of all eligible patients for CRC screening in the United States. Let that sink in. Three out of four eligible Americans can now access this test. ๐Ÿ”น Shield ...

Texas Hospitals Losing $27M/Day

By |September 12th, 2026|

A hospital CFO in Dallas sits down at his desk on Tuesday morning. ๐Ÿฅ His balance sheet looks the same as Monday. His Medicaid funding does not. As of September 1, 2026, Texas hospitals are losing $27 million a day in Medicaid reimbursement. According to the Texas Tribune, reporting published by ABC13, the Trump administration has withheld approval for about $9.8 billion in funding tied to three Medicaid programs. The biggest piece is the Comprehensive Hospital Increase Reimbursement Program, known as CHIRP, which helps hospitals cover the gap between what Medicaid pays and what care actually costs. This is not an abstract budget fight. This hits people. ๐Ÿ”น Four million low-income Texans are enrolled in Medicaid, most of them children. ...

Thyme Care $125M Series E

By |September 11th, 2026|

Cancer care just hit a $2B valuation. No hospital built it. A startup built on virtual navigation did. ๐ŸŽฏ Thyme Care raised $125 million in a Series E round this week, pushing its valuation above $2 billion, according to CNBC. That valuation roughly doubled from its Series D less than a year ago. Let that sink in for a second. The round was led by Morgan Health, with participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, and a16z Bio + Health. That is not a list of tourist investors. That is a signal. ๐Ÿ”น $125M raised in Series E ๐Ÿ”น Valuation now above $2 billion ๐Ÿ”น Services available to more than 10.5 million people across all 50 U.S. states ...

NSCLC Post-Treatment Nodule Framework

By |September 10th, 2026|

55% of NSCLC patients can still recur after curative-intent treatment. ๐ŸŽฏ That number should stop every radiologist and oncologist cold when they see a new nodule in a survivor. According to BioSpace, published studies report recurrence rates of approximately 20% to 55% for non-small cell lung cancer, depending on stage, treatment and other factors. And the National Cancer Institute estimates 230,000 new lung cancer diagnoses in 2026 alone, added to the more than 680,000 Americans already living with a prior lung cancer diagnosis as of January 1, 2025. That is a massive and growing surveillance burden. And most teams do not have a clean protocol for the hardest question: when a new nodule appears on post-treatment imaging, what does it ...

FQHCs grew 3.1% since OBBB passed

By |September 9th, 2026|

I read the new CMS data on FQHCs. The numbers surprised me. ๐Ÿ” Everyone told me the One Big Beautiful Bill would hollow out the safety net. The National Association of Community Health Centers warned that many community health centers were already making tough decisions about cutting back services, reducing essential staff, and closing sites. House Minority Leader Hakeem Jeffries said hospitals and community-based health centers were closing all throughout America. The data says something different. According to the Paragon Health Institute, drawing from comprehensive CMS enrollment data, here is what actually happened between July 1, 2025 and July 17, 2026: ๐Ÿ”น The number of FQHCs increased by 338, a 3.1 percent gain ๐Ÿ”น The number of Rural Health Clinics ...

Medicare Part D Premiums Rising in 2027

By |September 7th, 2026|

Are you ready for the bill your Medicare patients are about to get? ๐Ÿ’Š Because it just got more expensive to be on Medicare. The Trump administration announced it will end the Part D Premium Stabilization Demonstration after the 2026 plan year, one year earlier than originally planned. That program was the reason drug premiums stayed manageable for the past two years. Without it, according to Elder Law Answers, the national base beneficiary premium is projected to rise about 6 percent, from $38.99 per month in 2026 to $41.33 per month in 2027. Sounds small. But let me put this in context. Here is what is actually happening: ๐Ÿ”น Roughly 56 million people are enrolled in Medicare Part D drug ...

FOBT Screening Cuts CRC Death by 43%

By |September 6th, 2026|

A stool test mailed to your home. That is the intervention. No clinic visit. No prep. No procedure. Just a kit in the mailbox and the choice to use it. New research published in JAMA Network Open this week put hard numbers on exactly how much that choice matters, and the data stopped me cold. Researchers from the Karolinska Institutet in Stockholm tracked 376,511 people over a 13-year study period. They compared people invited to colorectal cancer screening to those who were not. Then they looked at who actually participated. Here is what they found, according to Clinical Briefing Report: - Being invited to screening: 26% lower colorectal cancer mortality - Actually participating in screening: 43% lower colorectal cancer mortality ...

Non-Metastatic NSCLC Consensus Map

By |September 3rd, 2026|

89 experts. 96 statements. Here is what they actually agreed on. ๐Ÿง  A modified Delphi process brought 89 thoracic oncology experts together for a 3-day in-person meeting in Barcelona last September. They rated 96 clinical statements on non-metastatic NSCLC. According to the Journal of Thoracic Oncology, consensus was achieved for 62 of those statements, 31 remained without consensus, and 3 were rejected outright. That means 1 in 3 statements could not reach agreement among the world's leading thoracic oncology minds. This is the most honest document in thoracic oncology right now. Not a guidelines memo. A real snapshot of where the field stands. Here is what the consensus actually said, by domain. ๐Ÿ“‹ THE NSCLC CONSENSUS CHECKLIST: AGREED vs. CONTESTED ...

HRSA $102M FQHC Expansion Reality Check

By |September 2nd, 2026|

FQHC CEO: Are you celebrating the $102M HRSA award or reading the fine print? ๐Ÿงพ Because the fine print is where your next two years live. On August 13, HHS announced $102 million in New Access Points awards through HRSA's Bureau of Primary Health Care. According to Granted Research, the awards go to 158 health centers to establish more than 415 new service delivery sites, expanding comprehensive primary care to nearly 1 million people. HHS called it the first major expansion of the Health Center Program since 2019. Secretary Kennedy called it the biggest investment in the program in two to three decades. That framing is real. And it deserves a reality check. ๐Ÿ“ Do the arithmetic. $102 million across ...